KINTARO Cells Power portends next stage of regenerative medicine
- KINTARO brings together about 50 years of fundamental Russian research on MSC therapy and 20 years of Japanese culturing expertise
Country Business Reports interviews and articles by Discovery Reports
Seeking to elevate the standards of regenerative medicine, industry pioneer KINTARO Cells Power anchors its quest on the legend of Kintaro, the Japanese folk hero that embodies youth, kindness and health. The company aims to fully automate cell culture cultivation.
Distinguished for successfully culturing first-class bone marrow-derived mesenchymal stem cells (BM-MSCs), KINTARO brings together about 50 years of fundamental Russian research on MSC therapy and 20 years of Japanese culturing expertise. The company boasts three patents for culturing BM-MSCs from young and healthy donors with broad-spectrum applicability. While awaiting three more patent approvals, it has trademarked “KINTARO Cells” in Japan, South Korea, Russia, Hong Kong, Taiwan, and many other countries. Across Southeast Asia, it pursues knowledge and technology transfer in hopes of evolving health practices.
“Our focus is on preventive medicine,” says Alexei Gladkov, founder and president. “For healthy people, we recommend prevention, while for those who already have some disease, KINTARO Cells can provide very good solutions.”
Gladkov vowed to propagate regenerative technology after bouncing back from heart failure 10 years ago using MSC treatment. Since MSCs differentiate into bone, muscle, fat and cartilage cells, MSC therapy holds potential for incurable diseases. KINTARO’s allogeneic treatment solutions are considered more efficacious because its cultivation technology can be applied universally and formulated within two weeks while retaining 88 per cent viability even after 36 hours.
KINTARO Cells will benefit countless patients globally once mass-produced. The KINTARO Robot Showroom and Factory featuring robotic process automation is opening soon. The lab is targeted for full operation by 2023, given recent findings that MSC treatment is effective against Covid-19 and in the prevention of other infectious diseases.
KINTARO invites like-minded investors, governments, hospitals and clinics to help bring forth the industry’s next stage and to explore pathways in a fast decision-making environment. Negotiations are ongoing in Singapore, Malaysia, Ukraine and Nepal for various partnerships.
“Now is the time for regenerative technology to reach society, so let’s do it together,” Gladkov says.